4//SEC Filing
HILL NANCY LOUISE 4
Accession 0001209191-20-042221
CIK 0001478320other
Filed
Jul 9, 8:00 PM ET
Accepted
Jul 10, 8:00 PM ET
Size
11.8 KB
Accession
0001209191-20-042221
Insider Transaction Report
Form 4
HILL NANCY LOUISE
Sr Vice President, Operations
Transactions
- Exercise/Conversion
Common Stock
2020-07-09$0.84/sh+17,400$14,616→ 27,400 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-07-09−17,400→ 100,600 totalExercise: $0.84Exp: 2023-11-03→ Common Stock (17,400 underlying) - Sale
Common Stock
2020-07-09$49.00/sh−17,400$852,600→ 10,000 total
Holdings
- 500(indirect: By Ryan Hill (son))
Common Stock
- 400(indirect: By Brandon Hill (son))
Common Stock
- 300(indirect: By Connor Hill (son))
Common Stock
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 21, 2020.
- [F2]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $49.00 to 49.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.
- [F4]The option is fully vested and exercisable.
Documents
Issuer
Adaptive Biotechnologies Corp
CIK 0001478320
Entity typeother
Related Parties
1- filerCIK 0001780790
Filing Metadata
- Form type
- 4
- Filed
- Jul 9, 8:00 PM ET
- Accepted
- Jul 10, 8:00 PM ET
- Size
- 11.8 KB